DocumentRX-5279
Issued
Read3 min

Glenmark files US FDA IND for three-target oncology drug ISB 2301

Ichnos Glenmark Innovation seeks FDA clearance for three-target ISB 2301 and plans 2027 Phase 1 solid-tumor studies, while Glenmark reports a 20.3% Q2 FY27 EBITDA margin.

TAG V-7932 · 597 words on the filing

Glenmark Pharmaceuticals Subsidiary Files US FDA IND Application For ISB 2301 - Sahi
Glenmark Pharmaceuticals Subsidiary Files US FDA IND Application For ISB 2301 - SahiBelova59 / pixabay

Summary of findings

  • Ichnos Glenmark Innovation submitted a US FDA IND application for ISB 2301.
  • ISB 2301 targets three tumor-associated antigens and engages T cells and NK cells.
  • Phase 1 evaluations in solid tumors are planned for 2027.
  • Q2 FY27 revenue reached ₹4,247.3 crore, up 20% on a like-for-like year-on-year basis.
  • Q2 FY27 EBITDA was ₹863.8 crore, with a 20.3% margin; adjusted PAT was ₹485.2 crore, with an 11.4% margin.

Glenmark Pharmaceuticals' innovation subsidiary, Ichnos Glenmark Innovation, submitted a US FDA Investigational New Drug application for ISB 2301, with Phase 1 evaluations in solid tumors scheduled to begin in 2027.

The submission moves ISB 2301 from preclinical IND-enabling work into formal FDA review. It does not constitute clearance to dose patients; FDA clearance remains the next gate before the planned 2027 study.

What does ISB 2301 target?

Sahi describes ISB 2301 as a first-in-class multispecific immune-cell activator for solid tumors. The antibody targets three tumor-associated antigens while engaging T cells and natural killer cells. That dual immune engagement aims to improve targeted antitumor immunity across solid-tumor indications.

Where does the development stand?

The IND filing followed completion of earlier preclinical evaluation and marks a formal regulatory step for a proprietary oncology asset. Sahi identified three trigger factors: FDA clearance of the IND application, initiation of Phase 1 patient dosing in 2027, and subsequent clinical safety and efficacy readouts.

Sahi assigned a medium-term trading horizon of 3-12 months and a bullish market bias, with Pharmaceuticals and Healthcare Biotechs rated overweight. Its view links the regulatory milestone to Glenmark's Q2 FY27 revenue base and profitability.

What do Glenmark's financials show?

Glenmark reported consolidated Q2 FY27 revenue of ₹4,247.3 crore, up 20% on a like-for-like year-on-year basis. Q2 EBITDA reached ₹863.8 crore, producing a 20.3% EBITDA margin. Adjusted profit after tax stood at ₹485.2 crore, with an adjusted PAT margin of 11.4%.

Those results support the established operating base while ISB 2301 remains in development. Sahi said the filing "underscores Glenmark's execution in advancing its novel biotherapeutics pipeline." Moving assets built on proprietary platform technologies into human trials can strengthen long-term innovation value within the broader portfolio.

What could delay or stop the program?

The principal regulatory risk is FDA non-clearance or a request for additional clinical-trial data. Development could also slip through delays in trial execution, while unexpected safety signals could alter the Phase 1 course. No FDA response date accompanied the filing announcement, so clearance timing remains undefined.

Sahi's commercial framing is deliberately long term. Early clinical progress produces no immediate revenue, but successful regulatory milestones can build intellectual-property value and potential licensing optionality. The program therefore adds strategic optionality rather than near-term sales.

Why do multispecific antibodies matter?

Within oncology research, multispecific antibodies represent an advancing therapeutic frontier. The approach seeks stronger targeted antitumor immunity by engaging both T cells and NK cells. ISB 2301's three-antigen design carries that platform concept into a formal US IND filing.

For pipeline investors, the filing marks procedural progress, not clinical validation. The next test is regulatory clearance, followed by Phase 1 dosing in 2027 and the first safety and efficacy readouts. Those data will provide the first patient-level evidence for the candidate.

What should portfolio managers watch?

The next near-term catalyst is FDA action on the IND application. The 2027 Phase 1 start and subsequent safety and efficacy data sit farther out, but they define the medium-term development path. Regulatory clearance could strengthen intellectual-property and licensing value; requests for more data, trial delays or safety findings could reset expectations.

Glenmark enters that sequence with Q2 FY27 revenue of ₹4,247.3 crore, a 20.3% EBITDA margin and an 11.4% adjusted PAT margin. The filing broadens its innovative-biologics exposure, while the reported operating performance provides the financial base against which investors will judge clinical execution.

via FDA industry wire (Google News) (Source)

Share this article:

More from Marcus Bennett

Marcus Bennett

Show full bio

News editor covering regulation, policy and their impact on global pharmaceutical industry at PharmInsider.

6 articles

Linked filings

  1. C-4460
  2. K-4971
  3. P-9899
  4. K-7275
  5. C-6506

Next filing »